Form 4: RxSight Officer Eric Weinberg Granted 32,218 RSUs

RxSight's Chief Business Development Officer, Eric Weinberg, was granted 32,218 restricted stock units, vesting over several years.

Summary

• Eric Weinberg, Chief Business Development Officer of RxSight, Inc. (RXST), was granted 32,218 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of RxSight's Common Stock.
• The RSUs will vest in six equal installments, with one-sixth vesting on or after August 31, 2026, February 28, 2027, August 31, 2027, February 28, 2028, August 31, 2028, and February 28, 2029.
• Vesting is contingent upon Mr. Weinberg continuing to be a Service Provider as defined in the Issuer's 2021 Equity Incentive Plan.
• Following this transaction, Mr. Weinberg beneficially owns 32,218 derivative securities (RSUs) directly.
• A Power of Attorney was executed on February 23, 2026, authorizing several individuals to prepare and file SEC reports on behalf of Eric Weinberg.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices aimed at aligning management incentives with long-term company performance and retention.

Positives

• The grant of 32,218 Restricted Stock Units (RSUs) aligns the Chief Business Development Officer's interests with those of shareholders, promoting long-term commitment and performance.
• The multi-year vesting schedule encourages executive retention and sustained focus on company growth and success.

Risks

• The vesting of RSUs is subject to the reporting person continuing to be a Service Provider, meaning forfeiture could occur if employment ceases before vesting dates.
• Future dilution of existing shareholder equity will occur as these RSUs convert into common stock upon vesting.

Future Outlook

The future outlook, as indicated by the RSU grant, suggests a continued commitment from the Chief Business Development Officer to RxSight's long-term success, with vesting scheduled through February 2029, contingent on continued service.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units to key executives is a standard practice in the biotechnology and medical device industries, serving as a common incentive for executive retention and performance alignment with shareholder interests. This type of compensation is typical for a company like RxSight, which operates in a specialized and competitive sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential future dilution as RSUs convert to common stock, but also increased alignment of executive interests with long-term shareholder value.
• Employees: The RSU grant to a key officer may signal stability and a commitment to executive retention within the company.

Next Steps

• The RSUs will vest in six tranches on specific dates between August 2026 and February 2029, subject to continued service.

Key Dates

Keywords

RxSight, RXST, Restricted Stock Units, RSU, Insider Transaction, Equity Grant, Executive Compensation, Form 4, SEC Filing